UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 22, 2011
COMPLETE GENOMICS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-34939 | 20-3226545 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) |
2071 Stierlin Court
Mountain View, California 94043
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (650) 943-2800
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 5.07 | Submission of Matters to a Vote of Security Holders. |
On June 22, 2011, Complete Genomics, Inc. (the “Company”) held its annual meeting of stockholders at its facility in Mountain View, California. The stockholders of the Company voted on the four proposals listed below. The final results for the votes regarding each proposal are set forth below. The proposals are described in detail in the Company’s Proxy Statement filed with the Securities and Exchange Commission on May 2, 2011.
1. Elect three Class I members of the Board of Directors to serve for a three-year term until the 2014 Annual Meeting of Stockholders or until their respective successors are elected and qualified or their earlier resignation or removal:
| Name |
Votes For |
Withheld | Abstentions | Broker Non-Votes |
||||||||||||
| Carl L. Gordon, Ph.D., CFA |
21,057,239 | 40,549 | — | 1,116,208 | ||||||||||||
| Lewis J. Shuster |
21,039,108 | 58,680 | — | 1,116,208 | ||||||||||||
| Charles P. Waite, Jr. |
21,043,326 | 54,462 | — | 1,116,208 | ||||||||||||
2. Advisory vote on executive compensation.
| Votes For |
Votes Against |
Abstentions |
Broker Non-Votes | |||
| 20,574,753 |
493,359 | 29,676 | 1,116,208 |
3. Advisory vote on the frequency of the advisory vote on executive compensation.
| 1 Year |
2 Years |
3 Years |
Abstentions | |||
| 3,877,575 |
5,948 | 17,183,974 | 30,291 |
4. Ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2011.
| Votes For |
Votes Against |
Abstentions |
Broker Non-Votes | |||
| 22,072,949 |
16,034 | 125,013 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: June 27, 2011 | COMPLETE GENOMICS, INC. | |||||
| By: | /s/ Ajay Bansal | |||||
| Name: Ajay Bansal | ||||||
| Title: Chief Financial Officer | ||||||